Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723265 | 0.82 | CYP1A2 (0.43) | CYP1A2GRM5DDB1CRBNALDH1A1 | |
| SCHEMBL13833544 | 0.81 | CYP1A2 (0.44) | CYP1A2GRM5PIM1PIM2PIM3 | |
| SCHEMBL13736491 | 0.81 | CYP1A2 (0.44) | CYP1A2GRM5MAOAMAOBDDB1 | |
| SCHEMBL13736789 | 0.81 | CYP1A2 (0.42) | CYP1A2GRM5MAOAMAOBDDB1 | |
| SCHEMBL1712005 | 0.80 | CYP1A2 (0.34) | CYP1A2GRM5MAOAMAOBDDB1 | |
| SCHEMBL19371052 | 0.74 | PIM1 (0.38) | PIM1PIM2PIM3ALDH1A1TDP1 | |
| SCHEMBL15540729 | 0.69 | CYP1A2 (0.51) | CYP1A2GRM5DDB1CRBNIKZF3 | |
| SCHEMBL13833170 | 0.68 | ALDH1A1 (0.40) | CYP1A2GRM5PIM1PIM2PIM3 | |
| SCHEMBL13833169 | 0.68 | ALDH1A1 (0.40) | CYP1A2GRM5PIM1PIM2PIM3 | |
| SCHEMBL1723397 | 0.68 | ALDH1A1 (0.40) | CYP1A2GRM5PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943485-B1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20150336960-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336960-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336960-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CYP1A2 4109/4885GRM5 3006/4885PIM1 1/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | CYP1A2 4109/4885GRM5 3006/4885PIM1 1/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CYP1A2 4109/4885GRM5 3006/4885PIM1 1/4885 |
| US-20150336960-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | PIM1, PIM2, PIM3 | CYP1A2 338/4885GRM5 1233/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.